Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427156 | 0.81 | SMN1; SMN2 (0.63) | — | |
| SCHEMBL21464147 | 0.80 | MGLL (0.39) | NPC1RAB9ATAAR1GAAFAAH | |
| SCHEMBL19750486 | 0.78 | TAAR1 (0.52) | NPC1RAB9ATAAR1GAAHSD17B10 | |
| SCHEMBL3432427 | 0.77 | NPC1 (0.59) | NPC1RAB9ATAAR1GAAMTNR1A | |
| SCHEMBL21891868 | 0.77 | NPC1 (0.49) | NPC1RAB9ATAAR1GAAMTNR1A | |
| SCHEMBL26174338 | 0.77 | SMN1; SMN2 (0.60) | NPC1RAB9ATAAR1GAAHSD17B10 | |
| SCHEMBL13055389 | 0.77 | TAAR1 (0.60) | NPC1RAB9ATAAR1GAAHSD17B10 | |
| SCHEMBL15941254 | 0.75 | BACE1 (0.32) | — | |
| SCHEMBL23447193 | 0.75 | IDO1 (0.53) | NPC1RAB9ATAAR1GAA | |
| SCHEMBL5108042 | 0.75 | TAAR1 (0.52) | NPC1RAB9ATAAR1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694874-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | Rubedo Life Sciences, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2024-12-12 | — | — | US | disclosed |
| WO-2024249613-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023193733-A1 | AT2R AGONIST | 武汉人福创新药物研发中心有限公司 | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX4 | NPC1 850/4885RAB9A 2614/4885TAAR1 3440/4885 |
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | NPC1 1727/4885RAB9A 3232/4885TAAR1 30/4885 |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | NPC1 1209/4885RAB9A 3340/4885TAAR1 3879/4885 |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | NPC1 1209/4885RAB9A 3340/4885TAAR1 3879/4885 |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | GPX4, GPX1, PRDX3 | NPC1 1209/4885RAB9A 3340/4885TAAR1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.